First Minister Nicola Sturgeon and Chief Medical Officer Catherine Calderwood visited highly rated biopharmaceutical startup EnteroBiotix yesterday at its groundbreaking facility at the Aberdeen Blood Transfusion Centre on the Foresterhill Health Campus as the company progresses towards the commercialisation of its products and a fresh round of external funding that will see the business through its next phase of growth.
Founded in 2017 by recently qualified doctor at the University of Aberdeen, 25-year old James McIlroy, EnteroBiotix develops faecal derived products for patients suffering from diseases associated with bacterial imbalances in the intestinal gut, with novel medicinal products that build on the clinical proven strategy of Faecal Microbiota Transplantation (FMT). FMT is the process of transferring bacteria from the gut of a healthy donor into the gut of a recipient thereby restoring a healthy balance
The company’s recently opened facility, one of the first of its kind globally, combines the use of an ISO:9001 accredited controlled donation facility with a GMP-ready clean room equipped with cutting edge isolator technology for the production of its faecal products for use in FMT. On the occasion of the First Minister’s visit, EnteroBiotix announced a pioneering collaboration with the Academic Health Science Partnership in Tayside and National Health Service to accelerate and catalyse the adoption of EnteroBiotix’s product line by NHS Tayside. The collaboration will involve clinical studies, a health economic analysis and the development of a business case for use of EnteroBiotix’s advanced products.
EnteroBiotix founder and CEO, Dr. James McIlroy, said: “The facilities and resources now available to us are game-changing for the company and our product pipeline. We now have a platform to develop products for patient use and clinical trials and our collaboration with NHS Tayside and the Academic Health Science Partnership gives us an enormous advantage moving forward as we look to establish ourselves as one of the main players in the fast-moving and exciting field of the microbiome.”
First Minister for Scotland, Nicola Sturgeon, said: “Scotland has a thriving life sciences sector that is renowned globally for innovation and its contribution to pioneering treatments for patients with serious medical conditions. Scottish companies like EnteroBiotix are testament to this. The research undertaken at this new facility will have a massive impact on future medical treatments for patients both here in Scotland and further afield.”
“The Scottish Government recognises the importance of creating the right environment to allow innovative companies, such as EnteroBiotix, to prosper and I’m pleased the Scottish Government, through Scottish Enterprise, has provided the support for them to grow.”
Chief Medical Officer for Scotland, Catherine Calderwood, said: “It is vital that new clinical treatments are developed to meet patient needs and EnteroBiotix is a good example of this. I welcome the announcement of their new partnership with NHS Tayside which will help progress this important research further.”
Subscribe to our newsletter to get stories like this delivered directly to your inbox